Madrigal Pharmaceuticals CMO Sells $516,561 in Resmetirom Stock
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
madrigal-pharmaceuticalsinsider-trading
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
David Soergel, Chief Medical Officer of Madrigal Pharmaceuticals, sold company shares worth $516,561 on June 1, 2026. The transaction involved 1,120 shares at an average price of $461.22, executed via a pre-arranged 10b5-1 trading plan. The sale occurred as the company’s shares traded approximately 13% below their 2026 high of $528.87 set in May. This transaction places the spotlight on insider liquidity events following the historic commercial launch of resmetirom, Madrigal’s therapy for metabolic dysfunction-associated steatohepatitis (MASH).
This sale is the first executive stock sale disclosed following Madrigal’s landmark FDA approval of resmetirom in March 2024. The drug became the first ever therapy approved for the liver disease MASH, estimated to affect over 6 million adults in the US. A comparable event occurred in January 2026, when another senior executive sold shares worth $1.2 million, according to SEC filings.
The macro backdrop features elevated scrutiny on biotech valuations, with the SPDR S&P Biotech ETF (XBI) up 22% year-to-date through late May. Interest rates remain a headwind, with the 10-year Treasury yield near 4.3%. The catalyst for the current focus is the completion of the critical post-launch phase. After the initial prescription ramp, investor attention has shifted to sustained commercial execution and long-term market share.
Madrigal’s stock surged 290% in the first five months of 2026, propelled by resmetirom’s successful launch and strong quarterly revenue beats. This dramatic appreciation creates natural conditions for executives to execute planned diversification sales. The market is now parsing these sales for signals about internal confidence in future growth rates beyond the initial launch euphoria.
The sale reduced Soergel’s direct holdings by approximately 3.5%, though he retains over 30,000 shares and substantial equity through options. The $461.22 average sale price compares to the stock’s closing price of $458.91 on the transaction date. Madrigal’s market capitalization stands at approximately $9.8 billion following this transaction.
The stock has significantly outperformed its sector and the broader market. While the XBI is up 22% YTD, Madrigal’s 290% gain dwarfs that performance. The S&P 500 has returned 8% over the same period. Resmetirom achieved over $150 million in net product revenue during its first full quarter of sales, exceeding analyst consensus estimates by more than 15%.
| Metric | Madrigal (MDGL) | Peer Avg. (Large-Cap Biotech) |
|---|---|---|
| YTD Return | +290% | +18% |
| Forward P/S Ratio | ~22x | ~8x |
| Short Interest | 5.2% of float | 4.1% of float |
Volume on the day of the sale disclosure was 1.8 million shares, 25% above the 30-day average. The stock’s 14-day relative strength index (RSI) was 45, indicating neutral momentum following its recent pullback from highs.
The sale introduces a test for sentiment around high-flying commercial-stage biotechs. Direct competitors like Akero Therapeutics and 89bio may see increased volatility as investors reassess post-approval valuation models. Companies with late-stage MASH candidates, such as Viking Therapeutics, could experience a slight negative read-through regarding perceived commercial enthusiasm from industry insiders.
The primary counter-argument is that this sale is a routine, planned diversification event. Executives often use 10b5-1 plans to schedule sales well in advance, insulating them from accusations of trading on non-public information. The transaction was relatively small compared to Soergel’s total remaining equity stake and the company’s $9.8 billion market cap.
Positioning data shows hedge funds remain net long Madrigal, but the elevated short interest of 5.2% suggests a cohort is betting on post-approvaluation compression. Flow is moving toward companies with earlier-stage metabolic disease pipelines seen as potential acquisition targets, given the validated multi-billion dollar MASH market.
The next major catalyst is Madrigal’s Q2 2026 earnings report, scheduled for late July. Analysts will scrutinize resmetirom’s prescription trend data, gross-to-net adjustments, and any updated revenue guidance. The American Association for the Study of Liver Diseases (AASLD) conference in November will feature real-world efficacy and safety data.
For the stock, key technical levels are the 50-day moving average near $440 and prior support at $420. A sustained break above $480 could signal renewed bullish momentum, while a close below $420 may indicate a deeper correction. Investors are also watching for any changes to consensus earnings estimates, which currently project 2026 revenue near $750 million.
Regulatory milestones for competing therapies, including potential FDA decisions for Viking Therapeutics’ candidate, will directly impact Madrigal’s perceived market exclusivity window. Any significant adjustments to Medicare or commercial insurer reimbursement for MASH therapies will be a critical fundamental watchpoint.
A Chief Medical Officer’s sale, especially via a pre-arranged plan, is rarely a direct signal on drug efficacy or clinical prospects. For retail investors, it is more indicative of personal financial planning and diversification after significant stock appreciation. The context is crucial: following a 290% gain, even bullish insiders may sell a portion of holdings to manage risk. It underscores the importance of focusing on commercial execution metrics like quarterly revenue and prescription growth rather than isolated insider transactions.
Historical analysis shows elevated insider selling is common in the 6-18 months following a landmark FDA approval, as lock-up periods expire and stock prices often peak. The magnitude of this sale, at just over half a million dollars, is modest compared to some precedents. For example, after the approval of a novel oncology drug in 2025, executives at another firm sold over $15 million in shares within a quarter. The scale of Madrigal’s sale suggests a measured approach to liquidity rather than a wholesale exit.
Madrigal’s stock was a pre-revenue biotech for years, trading below $100 for much of 2023. The catalyst for its meteoric rise was the positive Phase 3 data for resmetirom in late 2023, followed by FDA approval in March 2024. The stock entered the S&P MidCap 400 index in 2025 due to its growing market cap. Its current valuation multiples are being compared to other historic commercial-stage biotech launches, like Vertex Pharmaceuticals following the launch of its cystic fibrosis franchise, which also saw periods of high volatility and insider selling during its growth phase.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.